Prior research showed that higher flavonol consumption was associated with lower Alzheimer’s risk. This longitudinal study demonstrated that increased flavonol consumption yielded slower declines in global cognition and in episodic, semantic, and working memory, independent of other health and lifestyle factors.

In comparison to 72% of patients who received placebo, 45% of those who received teplizumab-mzwv (Tzield, Provention Bio) over the course of a median follow-up of 51 months were found to have stage 3 type 1 diabetes. Teplizumab-mzwv appeared to delay the onset of type 1 diabetes by about two years, as the median time from randomization to diagnosis of stage 3 diabetes was 50 months in the teplizumab-mzwv group and 25 months in the placebo group.

The new Moderna bivalent vaccine showed higher antibody development vs BA.4/BA.5 than the original version and also showed activity (although lower) against the new BQ1.1 strain. The Pfizer-BioNTech bivalent vaccine generated 3- to 5-fold higher antibody levels than the original vaccine against BA.4/.5 and 11-fold higher levels vs the newer variants.

The shortage is driven by increased prescribing due to bacterial infection coexisting with RSV infection, and in cases where it is not possible to tell if the patient is experiencing a bacterial or viral URI. Substitute antibiotics to consider include cephalosporins and amoxicillin-clavulanate.

Although the panel voted 16:1 for the new budesonide + albuterol inhaler in adults, they said the data does not support use in children and they were split on use in adolescents over the age of 12.

Anakinra (Kineret, Sobi) currently approved for rheumatoid arthritis and some rare disorders, was granted an emergency use authorization for a subgroup of COVID-hospitalized patients who are at risk of severe respiratory failure.